Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
✍ Scribed by M. Panisset; S. Gauthier; H. Moessler; M. Windisch; and The Cerebrolysin Study Group
- Publisher
- Springer
- Year
- 2002
- Tongue
- English
- Weight
- 103 KB
- Volume
- 109
- Category
- Article
- ISSN
- 1435-1463
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire
Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des
## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe